Goldman Sachs’s CareDx CDNA Stock Holding History

Goldman Sachs’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-60,000	Closed	-$5.49M	–	6248
2021 Q2	$5.49M	Buy	+60,000	New	+$4.77M	﹤0.01%	3259

Other funds holding CDNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Goldman Sachs's CDNA Position: Q1 2026 in Review

Goldman Sachs reduced its CareDx (CDNA) stake by 9.6% in Q1 2026, selling an estimated $1.47M and leaving 733,332 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

Goldman Sachs first reported a position in CDNA in Q3 2014 and has held it in 46 quarters since. The position peaked at $57.7M in Q2 2021. 190 funds tracked by Wall St. Rank hold CDNA as of Q1 2026.

Goldman Sachs held 733,332 shares of CareDx worth $12.7M as of Q1 2026.
Goldman Sachs sold 77,854 CareDx shares in Q1 2026, an estimated $1.47M.
CareDx made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2852 holding.
Goldman Sachs first reported a position in CareDx in Q3 2014 and has held it in 46 quarters since.
Goldman Sachs's CareDx position peaked at $57.7M in Q2 2021.
190 funds tracked by Wall St. Rank held CareDx as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.